Voyager Technologies enters the week of July 15 with a fresh Morgan Stanley downgrade, short interest pushing toward 20% of the float, and options positioning turning notably more defensive — a confluence that tightens the screws on an already pressured stock.
The analyst action is the sharpest new development. Morgan Stanley's Kristine Liwag cut VOYG to Underweight this morning, keeping her $39 target unchanged — a rare move that signals conviction in the direction rather than just a valuation reset. That puts the bellwether firm squarely in the bear camp. The broader analyst picture is divided: Wedbush trimmed its target from $60 to $46 on July 1 while holding its Outperform rating, and BTIG started coverage with a Buy and a $55 target in June. But with two Sell ratings and no Holds in the consensus, the Street's weight of opinion has turned negative. The bull case rests on the Starlab space station opportunity and a strong NASA backlog; the bear case centres on a 23% cut to NASA's FY27 budget request under the current administration, plus Starlab now slipping to a 2029-2030 launch window.
Short interest tells a consistent story of growing conviction on the short side. At roughly 20% of the free float — up 6.5% on the week and 27.6% over the past month — the position has grown steadily every week since early June, adding approximately 2.3 million shares in that span. The ORTEX short score of 72.6 ranks in the bottom 2nd percentile of the universe, one of the more extreme short-side readings across the market. Availability has tightened to around 47% — fewer than one share available for every two already on loan — and while that is well above the 52-week floor of 2.6%, the direction of travel is clearly toward a tighter borrow pool. Borrowing costs remain low at 0.65%, meaning shorts are still entering without friction, which in turn explains why the position keeps growing. The stock has now fallen roughly 28% over the past month to $29.78.
Options positioning shifted sharply on Tuesday. The put/call ratio jumped to 0.32, more than 2.5 standard deviations above its 20-day average of 0.25 — the highest defensive tilt in the available history, outside of a brief spike in late June. For context, the ratio had been running in a tight band around 0.235 for most of the past six weeks before this week's move. The jump suggests a sudden wave of downside hedging, likely connected to the Morgan Stanley action and the approach of the next earnings event on August 3.
Institutional flows add a nuanced counterpoint. BlackRock added 1.73 million shares in the quarter to June 30, building to a 4.6% stake. Tema ETFs and Tidal Investments each established new positions of roughly 1.3 million shares in the same period. That institutional buying, alongside Wellington and State Street adding modestly, provides a base of demand. But the two largest active holders — Senvest and Alyeska — both trimmed in the March quarter, each cutting by roughly 300,000 to 400,000 shares. The net picture is passive and ETF money flowing in while active managers pull back.
Earnings reaction history offers little comfort heading into August 3. The two most recent quarterly prints produced one-day losses of 5.3% and 8.3% respectively, with five-day losses of 16.9% and 19.7%. The one positive reaction in the dataset — a 4.1% gain — was followed by a 14.2% five-day gain, but that was the exception. The stock enters the August print down sharply, with shorts near a record position and the newly added Morgan Stanley Underweight providing fresh fundamental cover for the bearish thesis.
The focus heading into August 3 will be on any update to Starlab's launch timeline and whether management revisits its $4 billion revenue target given the NASA budget headwinds — with peer names LUNR and RKLB both down 16% and 5.5% on the week respectively, the entire commercial space cohort is under pressure and the sector backdrop provides little buffer.
See the live data behind this article on ORTEX.
Open VOYG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
